<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630500</url>
  </required_header>
  <id_info>
    <org_study_id>MEMPDD-130206</org_study_id>
    <nct_id>NCT00630500</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)</brief_title>
  <acronym>MEMPDD</acronym>
  <official_title>A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 24-week placebo-controlled parallel group multicentre trial to study the safety and
      efficacy of memantine in patients with dementia associated with Parkinson's disease and
      dementia with Lewy bodies. It is hypothesized that memantine will be safe and well tolerated,
      and more effective than placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression of Change</measure>
    <time_frame>Month 3 and 6 after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMSE</measure>
    <time_frame>Month 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's QUick Test</measure>
    <time_frame>Month 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Drug Research test</measure>
    <time_frame>Month 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory</measure>
    <time_frame>Month 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale, part III</measure>
    <time_frame>Month 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleep Scale</measure>
    <time_frame>Month 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stavanger Sleep Scale</measure>
    <time_frame>Month 3 and 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Dementia Associated With Parkinson's Disease</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <arm_group>
    <arm_group_label>Memantine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment with memantine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching active study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Tablets, 5 or 10 mg, twice daily</description>
    <arm_group_label>Memantine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets corresponding to 5 or 10 mg, twice daily, 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a diagnosis of Parkinson's disease (Larsen and Dupont, 1994) and dementia (DSM
             IV(1987; 1994), or Dementia with Lewy bodies (McKeith et al. Neurology 2005)

          -  mild-to-moderate or moderate dementia (i.e. MMSE 12-26, inclusive)

          -  the subject has given a written informed consent

          -  the subject is able and willing to comply with the study procedures and has a reliable
             caregiver (i.e. relative or nurse/nurse assistant who sees the patient at least
             weekly)

        Exclusion Criteria:

          -  other brain disease of sufficient severity to cause dementia

          -  mental retardation

          -  terminal illness with life expectancy shorter than 6 months

          -  recent major changes in health status

          -  known epilepsy or previous convulsive seizure

          -  major depression

          -  severe dementia as defined by a Mini-mental State Examination score of 12 or lower

          -  moderate to severe renal impairment (i.e. serum creatinine &gt; 1,5 upper limit normal
             (ULN) or creatinin clearance &lt; 40ml/minute/1,73 m2

          -  moderate or severe heart disease (NYHA III-IV)

          -  moderate or severe pulmonal disease

          -  moderate to severe hepatic impairment (bilirubin or transaminases &gt; 2 times ULN

          -  women of childbearing potential (i.e. not post-menopausal and not taking contraceptive

          -  the subjects is lactating

          -  any laboratory value(s) exceeding the limits of normality if deemed to be clinically
             relevant by the study physician

          -  known allergies to the investigational product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dag Aarsland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Stavanger HF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stavanger University Hospital, Old Age Psychiatry Clinic</name>
      <address>
        <city>Stavanger</city>
        <zip>4005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Memory Research Unit, Neuropsychiatric Clinic, University Hospital Malmo</name>
      <address>
        <city>Malmo</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Unit</name>
      <address>
        <city>Epping</city>
        <state>Essex</state>
        <zip>CM16 6TN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's COllege London</name>
      <address>
        <city>London</city>
        <zip>SE1 1UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia associated with Parkinson's disease</keyword>
  <keyword>Dementia with Lewy bodies</keyword>
  <keyword>Memantine</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Parallel group</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

